The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
Open accessAbstract
Background: Second-generation antipsychotics have been thought to cause fewer extrapyramidal side-effects (EPS) than first-generation antipsychotics, but recent pragmatic trials have indicated equivalence. Aims: To determine whether second-generation antipsychotics had better outcomes in terms of EPS than first-generation drugs. Method: We conducted an intention-to-treat, secondary analysis of data from an earlier randomised controlled trial (n= 227). A clinically significant difference was defined as double or half the symptoms in groups prescribed first-v.second-generation antipsychotics, represented by odds ratios greater than 2.0 (indicating advantage for first-generation drugs) or less than 0.5 (indicating advantage for the newer drugs). We also examined EPS in terms of symptoms emergent at 12 weeks and 52 weeks, and symptoms that had resolved at these time points. Results: At baseline those randomised to the first-generation antipsychotic group (n= 118) had similar EPS to the second-generation group (n= 109). Indications of resolved Parkinsonism (OR = 0.5) and akathisia (OR = 0.4) and increased tardive dyskinesia (OR = 2.2) in the second-generation drug group at 12 weeks were not statistically significant and the effects were not present by 52 weeks. Patients in the second-generation group were dramatically (30-fold) less likely to be prescribed adjunctive anticholinergic medication, despite equivalence in terms of EPS. Conclusions: The expected improvement in EPS profiles for participants randomised to second-generation drugs was not found; the prognosis over 1 year of those in the first-generation arm was no worse in these terms. The place of careful prescription of first-generation drugs in contemporary practice remains to be defined, potentially improving clinical effectiveness and avoiding life-shortening metabolic disturbances in some patients currently treated with the narrow range of second-generation antipsychotics used in routine practice. This has educational implications because a generation of psychiatrists now has little or no experience with first-generation antipsychotic prescription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cited by
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Baptista, P. P. A., de Senna, P. N., Paim, M. F., Saur, L., Blank, M., do Nascimento, P., Ilha, J., Vianna, M. R. M., Mestriner, R. G., Achaval, M., et al. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.020 · Cited by 23
Metadata
- Authors
- Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2012-05
- Volume
- 200
- Issue
- 5
- Pages
- 387-392
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2139278291
- Cited by
- 196
- References
- 1
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. https://app.cochat.ai/papers/10.1192/bjp.bp.111.101485
- The paper
- Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B. (2012). Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.111.101485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.